Fiduciary Trust’s Royalty Pharma RPRX Stock Holding History

Fiduciary Trust’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$340K	Hold	6,065	–	–	﹤0.01%	713
2026 Q1	$291K	Buy	+6,065	New	+$266K	﹤0.01%	743

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiduciary Trust's RPRX Position: Q2 2026 in Review

Fiduciary Trust held its Royalty Pharma (RPRX) position steady in Q2 2026 at 6,065 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #713.

Fiduciary Trust first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Fiduciary Trust held 6,065 shares of Royalty Pharma worth $340K as of Q2 2026.
Fiduciary Trust left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up ﹤0.01% of Fiduciary Trust's portfolio in Q2 2026, its #713 holding.
Fiduciary Trust first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.